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ABSTRACT
OBJECTIVE: To analyze the costs of vaccination regimens for introducing 
inactivated polio vaccine in routine immunization in Brazil.
METHODS: A cost analysis was conducted for vaccines in five vaccination 
regimens, including inactivated polio vaccine, compared with the oral polio 
vaccine-only regimen. The costs of the vaccines were estimated for routine 
use and for the “National Immunization Days”, during when the oral polio 
vaccine is administered to children aged less than five years, independent 
of their vaccine status, and the strategic stock of inactivated polio vaccine. 
The presented estimated costs are of 2011.
RESULTS: The annual costs of the oral vaccine-only program (routine and 
two National Immunization Days) were estimated at US$19,873,170. The 
incremental costs of inclusion of the inactivated vaccine depended on the 
number of vaccine doses, presentation of the vaccine (bottles with single 
dose or ten doses), and number of “National Immunization Days” carried 
out. The cost of the regimen adopted with two doses of inactivated vaccine 
followed by three doses of oral vaccine and one “National Immunization 
Day” was estimated at US$29,653,539. The concomitant replacement of 
the DTPw/Hib and HepB vaccines with the pentavalent vaccine enabled 
the introduction of the inactivated polio without increasing the number of 
injections or number of visits needed to complete the vaccination.
CONCLUSIONS: The introduction of the inactivated vaccine increased 
the annual costs of the polio vaccines by 49.2% compared with the oral 
vaccine-only regimen. This increase represented 1.13% of the expenditure 
of the National Immunization Program on the purchase of vaccines in 2011.
DESCRIPTORS: Poliomyelitis, prevention & control. Poliovirus 
Vaccine Inactivated, supply & distribution. Poliovirus Vaccine Oral, 
supply & distribution. Immunization Programs, organization & 
administration. Cost analysis.
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With the Global Polio Eradication Initiative of the 
World Health Organization (WHO), the number of 
paralytic poliomyelitis (polio) cases decreased more 
than 99.0% (from 350,000 in 125 endemic countries 
in 1988 to 416 cases in 2013). Four WHO regions 
have been certified to be polio-free; wild poliovirus 
type-2 was globally eliminated in 1999, and no new 
cases of wild poliovirus type-3 have been reported 
since November 2012.23
Despite huge advances toward polio eradication, 
achieving total success has been more difficult than 
anticipated. Infection continues occurring due to subop-
timal effectiveness of the oral polio vaccine (OPV) 
in tropical countries; and, mainly due to difficulties 
in achieving and sustaining sufficiently high vaccine 
coverage, particularly in conflict zones or difficult-to-
access areas.21 Many countries still lack basic sanitation, 
which is important for controlling polio transmission. 
Three countries (Afghanistan, Pakistan, and Nigeria) 
RESUMO
OBJETIVO: Analisar os custos de esquemas de vacinação para a introdução da 
vacina inativada de pólio na imunização de rotina no Brasil.
MÉTODOS: Foi realizada análise de custos das vacinas de cinco esquemas de 
vacinação, incluindo vacina pólio inativada, comparados ao esquema apenas-
vacina oral de pólio. Foram estimados custos das vacinas para rotina, para os 
“Dias Nacionais de Imunização”, quando a vacina de pólio oral é administrada 
para menores de cinco anos, independentemente da situação vacinal, e do estoque 
estratégico de vacina pólio inativada. Os custos estimados foram os de 2011.
RESULTADOS: Os custos anuais do programa apenas-vacina de pólio oral 
(de rotina e de dois Dias Nacionais de Imunização) foram estimados em 
US$19.873.170. Os custos incrementais da inclusão da vacina pólio inativada 
dependeram: do número de doses da vacina, da apresentação da vacina (frascos 
com dose única ou dez doses) e do número de “Dias Nacionais de Imunização” 
realizados. O esquema adotado, com duas doses de VIP seguidas de três doses 
de VOP e um “Dia Nacional de Imunização”, foi estimado em US$29.653.539. 
A concomitante substituição das vacinas DTPw/Hib e HepB pela vacina 
pentavalente permitiu a introdução da vacina pólio inativada sem aumento do 
número de injeções ou visitas necessárias para completar a vacinação.
CONCLUSÕES: A introdução da vacina pólio inativada aumentou os custos 
anuais das vacinas de pólio em 49,2%, comparado ao esquema apenas-vacina de 
pólio oral. Esse aumento representou 1,13% dos gastos do Programa Nacional 
de Imunização com a compra de vacinas em 2011.
DESCRITORES: Poliomielite, prevenção & controle. Vacina Inativada 
de Pólio, provisão & distribuição. Vacina Oral de Pólio, provisão & 
distribuição. Programas de Imunização, organização & administração. 
Análise de Custos.
INTRODUCTION
have never interrupted wild poliovirus transmission.23 
Viruses from these countries have caused outbreaks in 
neighboring countries that had already eliminated polio, 
such as the 2013 outbreaks in Somalia and Syria.4,22
The WHO polio eradication strategy is based on the use 
of OPV. Although effective and safe, in rare cases, this 
attenuated vaccine strain may cause vaccine-associated 
paralytic poliomyelitis (VAPP), which is clinically indis-
tinguishable from polio caused by wild poliovirus.15,23 
Annual VAPP incidence is estimated at two to four cases 
per million births in countries using OPV.10,15,19,23
The vaccine strain is transmitted to the vaccinees’ 
contacts by the fecal-oral or oral-oral route and may 
spread in populations with low vaccine coverage. This 
strain is genetically unstable and may regain neurovir-
ulence during the transmission chain in the commu-
nity.6,15 This circulating vaccine-derived poliovirus 
(cVDPV) has been associated with outbreaks of para-
lytic polio.6 Although the three types of polio vaccine 
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strains may convert to cVDPV, most reported cVDPV 
outbreaks are related to the type-2 virus.6,23 Seven coun-
tries reported cases of paralytic polio caused by cVDPV 
in 2013, all of them caused by the type-2 virus. Polio 
eradication will be fully achieved only when OPV 
ceases to be used in the world.15,23
Wild poliovirus transmission was interrupted in Brazil in 
1989 and the Americas were declared polio-free in 1994. 
The immunization actions after 1994 have been aimed 
at preventing reintroduction of the wild poliovirus in the 
region.7,14 The polio vaccination strategy of the Brazilian 
National Immunization Program (NIP) comprised five 
OPV doses during routine immunization of children, along 
with two annual campaigns [National Immunization Days 
(NID)] for administering OPV to all children under five 
years of age, independent of their vaccination status. This 
strategy remained the same from the 1980s up to 2012.7,14 
OPV is widely accepted by the Brazilian population, and 
high vaccine coverage has been maintained. A National 
Vaccination Coverage Survey reported 96.0% coverage 
for the third dose of polio vaccine among 18-month-old 
children in 2007.5 In March 2014, for the first time since 
polio elimination, wild poliovirus type-1 was detected 
in sewage samples collected at Viracopos International 
Airport in Campinas, SP, Southeastern Brazil.a However, 
to date, no cases of paralytic polio due to wild poliovirus 
have been detected in Brazil.a
Vaccine polio strains have been the only cause of para-
lytic polio in Brazil in the post-elimination period. The 
Surveillance of Acute Flaccid Paralysis program regis-
tered 46 confirmed VAPP cases between 1989 and 2010; 
this reflects an average of 2.1 cases per year, with an 
estimated risk of one VAPP case per 4.5 million initial 
OPV doses. As in other polio-free countries and regions, 
the risk of VAPP in Brazil has been higher than the risk 
of wild poliovirus importation.
A safer inactivated polio vaccine (IPV) is available; 
studies have demonstrated IPV’s high immunoge-
nicity and efficacy in tropical areas.3,8,23 However, 
IPV is more expensive than OPV, and switching from 
all-OPV immunization schedules to schedules including 
IPV would not be cost-effective.2,9,12,20 Many high- and 
medium-income countries have already replaced the 
all-OPV schedule with sequential IPV-OPV or all-IPV 
schedules.17,18 These countries switched to IPV to avoid 
VAPP despite the additional cost.1,18
Until 2012, IPV was available in Brazil at public health 
immunization referral centres only for children with 
OPV contraindication: immunocompromised children, 
HIV-exposed children, and children in contact with immu-
nocompromised persons. IPV was also available from 
private clinics. Both the Brazilian Paediatric Society and 
the Brazilian Immunization Society recommended IPV use 
for routine polio immunization, particularly for the first two 
doses. Nevertheless, children from the higher socioeco-
nomic strata were vaccinated with IPV in the private sector; 
low-income children, dependent on the Brazilian Unified 
Health System, continued to receive OPV and were at risk 
of VAPP, increasing inequities. Brazilian medical societies 
exerted pressure on the Ministry of Health for changes in 
the national polio immunization policies. The Brazilian 
Ministry of Health decided to introduce a sequential 
IPV-OPV schedule in routine immunization in August 2012. 
This routine included administration of IPV in the first two 
doses, followed by three OPV doses and one annual NID, 
with OPV administered to all children aged 6-59 months, 
independent of their immunization status.
Countries considering incorporating IPV into their NIP 
should evaluate its epidemiological, financial, and opera-
tional implications. Before adopting the new polio vacci-
nation program, the Brazilian Ministry of Health commis-
sioned a broad-spectrum health technology assessment 
of IPV introduction in routine childhood immunization.
The present study is part of this assessment; its purpose 
was to analyze the costs of including IPV in routine 
immunization vaccine schedules in Brazil.
METHODS
We conducted a search of the WHO website to identify 
polio immunization schedules including the use of IPV in 
different countries; our findings are shown in Table 1. Five 
different schedules were considered as effective alternatives 
for including IPV in routine childhood immunization: (1) 
a sequential schedule with one IPV dose followed by four 
OPV doses; (2) a sequential schedule with two IPV doses 
followed by three OPV doses; (3) a sequential schedule 
with three IPV doses followed by two OPV doses; (4) an 
all-IPV schedule composed of four IPV doses; and (5) 
all-IPV schedule composed of five IPV doses.
Cost estimates of different vaccination schedules 
including IPV were developed on the basis of the NIP 
Information System and NIP Coordination information. 
These estimates were then compared with the national 
annual costs of the all-OPV schedule (routine immu-
nization + two NID).
The study was performed from the perspective of 
the health care system and only the vaccine purchase 
costs were considered. All costs were estimated in 
the 2011 Brazilian real (R$) and presented in United 
States dollars (US$) at the December 30, 2011, 
exchange rate of US$1.00 = R$1.88.b
a WHO Global Alert and Response. Detection of poliovirus in sewage, Brazil. Geneva; 2014 [cited 2014 Jul 28]. Available from: http://www.
who.int/csr/don/2014_6_23polio/en/
b Banco Central do Brasil. Taxas de câmbio. Brasília (DF); 2011 [cited 2012 Nov 15]. Available from: http://www.bcb.gov.br/?txcambio
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Costs of vaccines for routine immunization (OPV and 
IPV) and NID (only OPV) were estimated separately. 
One or two yearly NID were considered as equally 
valid alternatives to assure high vaccination coverage 
during transition from all-OPV to a schedule including 
IPV. The mean number of OPV doses administered 
in the two NID conducted in 2010, reported by NIP 
Coordination, was considered as the reference for esti-
mating costs of one NID.
To estimate the number of doses needed in a routine polio 
immunization protocol, we used the numbers of OPV and 
IPV doses administered in Brazil in 2010. These data 
were obtained from the NIP Information System.c We 
assumed that the vaccination coverage of IPV-including 
schedules would be the same as for all-OPV schedules.
We assumed that a complete series of IPV doses 
would be administered to all children for whom OPV 
is contraindicated, according to the IPV doses admin-
istered in 2010.
The estimated number of vaccines needed included 
the number of administered doses plus a wastage rate. 
The OPV wastage rate was estimated on the basis of 
the number of doses distributed throughout Brazil in 
2010 (reported by NIP Coordination) and the number 
of administered doses, as obtained from DATASUSc:
Oral polio vaccine wastage rate (%) = (Number of 
distributed doses - Number of administered doses) × 100
Number of distributed doses
IPV wastage rate estimates were based on WHO 
recommendations.d Two different wastage rates were 
considered depending on the IPV dose presenta-
tion: 5.0% for single-dose vials and 25.0% for liquid 
vaccines in 10-20-dose vials.
A strategic vaccine stock was included in the estimated 
number of doses required for the first year of the vacci-
nation program. The extra vaccine supply is intended to 
Table 1. 2011 polio vaccination schedules including IPV, by country.
Immunization Schedules Country or Countries (number of vaccine doses)
Sequential schedules with 2 doses of OPV 
followed by IPV (4 doses)
South Africa (2 OPV, 4 IPV)
Sequential schedules with 1 dose of IPV 
followed by OPV (4-6 doses)
Bahrain (1 IPV, 4 OPV), Kuwait (1 IPV, 4 OPV), Oman (1 IPV, 5 OPV), Qatar (1 
IPV, 4 OPV), Saudi Arabia (1 IPV, 4 OPV), United Arab Emirates (1 IPV, 4 OPV)
Sequential schedules with 2 doses of IPV 
followed by OPV (3-5 doses)
Bermuda (2 IPV, 4 OPV), Jordan (2 IPV, 4 OPV), Syrian Arab Republic (2 IPV, 4 
OPV), Ukraine (2 IPV, 4 OPV)
Sequential schedule with 3 doses of IPV 
followed by OPV (1-5 doses)
Belarus (3 IPV, 3 OPV), Poland (3 IPV, 1 OPV), Russian Federation (3 IPV, 
3 OPV), Marshall Islands (3 IPV, 5 OPV), Indonesia (part of the country has 
implemented 3 doses of IPV)
Sequential schedule with 4 doses of IPV 
followed by OPV (2 doses)
Malaysia (4 IPV, 2 OPV), Russia (4 IPV, 2 OPV), Turkey (4 IPV, 2 OPV)
All-IPV schedule in routine and OPV in 
campaigns
Costa Rica (4 IPV, 1 annual campaign for children aged 2 months to < 5 
years, independent of previous vaccination history), Mexico (4 IPV, 3 annual 
campaigns for children aged 6 months to < 5 years with at least 2 previous 
doses of IPV)
All-IPV schedule Andorra (4), Australia (3 or 4a), Austria (4), Belgium (3 or 5b), Bosnia and 
Herzegovina (4c), Bulgaria (4), Canada (5), Croatia (6), Cyprus (5), Czech 
Republic (5), Denmark (4), Estonia (5), Finland (4), France (6), Germany (4 or 
5 dosesb), Greece (4), Hungary (5), Iceland (4), Ireland (4), Israel (5), Italy (4), 
Latvia (6), Lithuania (5), Luxembourg (5), Malta (5), Monaco (3), Netherlands 
(6), New Zealand (4), Niue (4), Norway (5), Palau (4), Portugal (4), Romania 
(5), San Marino (4), Slovakia (5), Slovenia (4), Spain (4), South Korea (4), 
Sweden (4), Switzerland (5), United Kingdom (5), United States of America (4)
Source: World Health Organization. Available from: http://www.who.int/countries/en/ Accessed on May 1, 2012.
OPV: oral polio vaccine; IPV: inactivated polio vaccine
a Different regions of the country use different schedules.
b Higher number of doses if combined vaccine, lower number of doses if IPV separately.
c Only part of the country uses all-IPV, another part of the country uses OPV.
Lebanon would start immunization with IPV in 2011, but no further information could be found.
c Ministério da Saúde, DATASUS. Informações de Saúde (TABNET): Assistência à Saúde: imunizações desde 1994: doses aplicadas [tabela]. 
Brasília (DF); 2014 [cited 2014 Nov 24]. Available from: http://www2.datasus.gov.br/DATASUS/index.php?area=0202&VObj=http://tabnet.
datasus.gov.br/cgi/deftohtm.exe?pni/cnv/dpni
d World Health Organization. Immunization service delivery: projected vaccine wastage. Geneva [cited 2014 Mar 19]. Available from: http://
apps.who.int/immunization_delivery/systems_policy/logistics_projected_wastage/en/index.html
e World Health Organization, Department of Vaccines and Biologicals. Guidelines for estimating costs of introducing new vaccines into the 
national immunization system. Geneva; 2002 [cited 2014 Mar 19]. Available from: http://whqlibdoc.who.int/hq/2002/WHO_V&B_02.11.pdf
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be distributed throughout Brazil.e Costs of a strategic 
IPV vaccine stock, set at 25.0% of the vaccine needs 
for routine immunization, were estimated separately.
OPV costs were estimated on the basis of the price 
paid by the Brazilian Ministry of Health in 2011 
(US$0.36 per dose in 20- or 25-dose presentation) 
(NIP Coordination). IPV costs were estimated on the 
basis of different prices according to the presentation 
size: the price paid by the Brazilian Ministry of Health 
in 2011 to conduct target group vaccination (US$4.63 
per dose) for IPV presented in single-dose vials and the 
price negotiated between the Ministry of Health and 
the vaccine producer for IPV introduction in routine 
childhood immunization (US$2.67 per dose) for IPV 
presented in 10-dose vials.
Vaccine cost estimates were based on the following 
steps: identification, estimation of necessary resources, 
and valuation. The estimated resources were multiplied 
by the prices (unit costs) to estimate total vaccine costs:
• OPV costs = (Number of estimated administered 
doses + OPV wastage rate) × price of the OPV dose
• IPV costs = (Number of estimated administered 
doses + IPV wastage rate) × price of the IPV dose
• Total costs for routine immunization schedule = 
OPV (routine) costs + IPV costs
IPV introduction in childhood immunization was 
planned to occur simultaneously with substitution of the 
diphtheria-tetanus-whole cell pertussis/Haemophilus 
influenzae b (DTPw/Hib) and hepatitis B (HepB) 
vaccines for a pentavalent vaccine (DTPw/Hib/HepB). 
The numbers of required injections for each child would 
not change due to this change. Costs of syringes, safety 
boxes, and health professionals’ vaccine administra-
tion time were considered to remain the same using 
the new immunization protocol as in the old and were 
not included in the analysis.
We estimated the vaccine volume per fully-immu-
nized child for the “former immunization schedule” 
(DTPw/Hib + HepB + OPV) and for the “new 
schedule” (pentavalent + IPV-OPV) to assess the need 
for expanding the cold storage chain needed to support 
IPV introduction.
Vaccine volume per fully-immunized child was 
calculated by multiplying vaccine volume-per-
dose (with vaccines stored in secondary packaging) 
by the number of doses per child, multiplied by a 
wastage factor.f Volume-per-dose was estimated 
for the vaccines produced in Brazil (DTPw/Hib 
and hepB) according to the size of the secondary 
package and the number of doses per box. In cases 
of internationally produced vaccines, we consid-
ered the volume-per-dose published in literature.
The wastage factor was calculated by the formula:
Wastage factor = 1/(1 - wastage rate)
The wastage rates used for these estimates were as 
follows: 5.0% for all single-dose vials; 10.0% for liquid 
and lyophilized vaccines in 5-dose vials; and 25.0% for 
liquid vaccines in 10-dose vials. The wastage rate of 
OPV was estimated on the basis of the number of doses 
administered and distributed in Brazil in 2010.
RESULTS
According to NIP Coordination, 59,376,500 OPV doses 
were distributed for both routine immunization and 
NID. As shown in Table 2, a total of 41,783,381 OPV 
doses were administered; the wastage rate was 29.6%.
The cost of OPV administered in each NID was esti-
mated at US$6,800,740.00, depending on the average 
number of doses (14,691,390) administered during 
the two NID conducted in 2010 and the wastage rate.
Compared with the all-OPV schedule, including IPV 
in routine childhood immunization may change annual 
vaccine costs from -26.5% to +275%, depending on 
the number of IPV doses in the schedule, the IPV 
presentation size, and the number of NID conducted, 
not considering the strategic stock. These changes are 
shown in Table 3.
As illustrated in Schedule 2, Table 3, for scheduling 
1 annual polio NID, the Ministry of Health purchased 
IPV in 10-dose vials and adopted a routine sequen-
tial immunization schedule with two IPV doses 
followed by three OPV doses. This program annu-
ally cost US$29,653,539 for purchasing the vaccine, a 
49.2% increase compared with the all-OPV program 
(US$19,873,170), not considering the cost of the IPV 
strategic stock: US$3,962,975 in the first year of the 
program (Table 3). This increase (US$9,780,369) 
represented 1.1% of the 2011 NIP vaccine purchase 
expenditure (US$862,355,593, as reported by NIP 
Coordination). Considering IPV purchased using the 
10-dose presentation and 1 annual NID, the incre-
mental costs of each additional dose of IPV in the 
schedule would be US$1,535,989 for the first dose; 
US$8,244,380 for the second dose; US$8,430,273 for 
the third dose; US$7,653,475 for the fourth dose, and 
US$2,744,712 for the fifth dose.
f Brenzel L, Jones A, et al. Immunization financing toolkit: a resource for policy-makers and program managers. Washington (DC): The World 
Bank; 2010 [cited 2014 Mar 19]. Available from: http://www.who.int/immunization_financing/tools/final_toolkit_2011.pdf 
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As shown in Table 4, the cold chain needs assessment 
revealed that the new polio vaccination schedule saved 
space in the cold storage chain.
DISCUSSION
The decision to introduce IPV in the Brazilian child-
hood routine immunization program was driven by 
ethical issues. VAPP is unacceptable in the absence 
of wild poliovirus circulation. Considering the high 
acceptability of OPV in Brazil and its substitution 
by an injectable vaccine, retaining use of OPV in the 
early phases of the new polio immunization program is 
deemed important to ensure high vaccination coverage 
in Brazilian society. Sequential IPV-OPV schedules 
reduce the risk of VAPP while maintaining high levels 
of intestinal mucosal immunity conferred by OPV.23 
The effectiveness of two doses in preventing paralytic 
polio was estimated at 89.0% (95%CI 62.0;97.0).16 
In the US, switching from an all-OPV to a sequen-
tial IPV-OPV schedule, with IPV used in the first two 
doses, led to a 54.3% reduction in VAPP cases.1 No 
VAPP cases occurred in recipients of the sequential 
IPV–OPV schedule.1
Among the 46 VAPP cases reported in Brazil from 1989 
to 2010, 17 occurred after the first OPV dose, 10 after 
the second, 4 after the third, and four after the fourth 
dose; eight occurred among those in contact with a 
vaccinated child and in three cases, information was 
not available (Surveillance of Acute Flaccid Paralysis). 
The sequential schedule with IPV in the first two doses 
would avoid at least 58.7% of such cases. However, 
studies report that the risk of VAPP and cVDPV will 
cease only by eliminating OPV use.15,23
As illustrated in Table 1, vaccination schedules 
including IPV are not mutually exclusive; they may 
be seen as steps for switching from an all-OPV to an 
all-IPV program. More doses of IPV may be introduced 
as soon as higher vaccination coverage is assured, 
provided there is sufficient funding and sustainable 
vaccine supply. This transition strategy has already been 
successfully used by other countries such as the US.1
This study is part of a collaboration with NIP managers 
to support decision making regarding the incorpora-
tion of new vaccines. Countries considering including 
IPV in routine childhood immunization must be able to 
guarantee long-term IPV supply, and price is definitely 
a relevant factor. Assessment of the financial impact of 
immunization interventions is important to determine 
long-term resource requirements and their impact on 
the government budget.
A trade-off between price (higher for single-
dose vials) and wastage rate (higher for multi-
dose vials) should be considered when choosing 
vaccine presentation. Ten-dose presentation saved 
the Brazilian government money as compared with 
a single-dose presentation. However, our costs 
of vaccination schedules with IPV in single-dose 
presentation could be overestimated, because we 
considered the price (US$4.63 per dose) paid by 
the Ministry of Health in 2011 to purchase IPV for 
immunizing target groups. The Ministry of Health 
would probably get a lower price for utilizing IPV 
in universal childhood immunization, although it 
would not be as low as in the 10-dose presentation. 
On the other hand, cost estimates of vaccination 
schedules with IPV in 10-dose presentation were 
based on the price (US$2.67) negotiated between 
the Ministry of Health and the producer to intro-
duce IPV in routine immunization.
An important cost and operational factor of IPV intro-
duction in Brazil was the concomitant substitution of 
DTPw/Hib and HepB vaccines by a pentavalent combi-
nation vaccine. This strategy allowed the Ministry of 
Health to introduce IPV in childhood immunization 
without increasing the number of clinic visits or the 
number of injections necessary to complete immuni-
zation and without additional vaccine administration 
costs. Increasing the numbers of visits or injections 
required for basic immunization increases the likelihood 
Table 2. Numbers of oral and inactivated polio vaccine doses administered in routine childhood immunization and NID. Brazil, 2010.*
Vaccine 1st dose 2nd dose 3rd dose 4th dose 5th dose
Total 
Routine
1st NID 2nd NID
Total
Routine + 
2 NID
OPV 2,964,284 2,873,602 2,938,396 2,807,857 816,461 12,400,600 14,475,967 14,906,814 41,783,381
IPV 42,710 23,312 19,866 15,921 7,304 109,113 0 0 109,113
OPV + 
IPV
3,006,994 2,896,914 2,958,262 2,823,778 823,765 12,509,713 14,475,967 14,906,814 41,892,494
Source: DATASUS. Available from: www.datasus.gov.br >Informações em Saúde(TABNET)>Assistência à Saúde>/
Imunizações/Doses Aplicadas
OPV: oral polio vaccine; IPV: inactivated polio vaccine; NID: National Immunization Day
* Routine childhood immunization was based on OPV. IPV was available at public health immunization referral centres only 
for immunocompromised children, HIV-exposed children, and children in contact with immunocompromised persons. In 
NID, OPV was administered to all children aged 0-5 years, independent of their immunization status.
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Table 4. Characteristics of vaccine presentation and the estimated vaccine storage volume per fully-immunized child for the “former 
immunization schedule” (all-OPV + DTPw/Hib + HepB) and for the “new schedule” (IPV-OPV + DTPw/Hib/HepB). Brazil, 2011.
Number of doses 
per vial and 
number of vials 
per package
Vaccine volume 
per dose (cm3)
Number of doses 
per FIC
Wastage factora
Vaccine storage 
volume per FICb 
(cm3)
Liquid + 
lyophilized 
tetra: DTPw/
Hib (Butantan/
BioManguinhos) 
5-dose vials in a 
box of 5 
18.8 3 1.1 62.8
HepB (Butantan) 10-dose vial in a 
box of 20 
4.1 3 1.3 16.3
OPV 
(BioManguinhos)
25-dose vial in a 
box of 100
1.0 3 1.4 4.3
Former schedule (DTPw/Hib + HepB + OPV) 83.4
Liquid penta 
(DTPw/Hib/HepB)
1-dose vial in a 
box of 50
12.9 3 1.0 40.7
IPV 1-dose vial in a 
box of 50
12.9 2 1.0 27.2
IPV 10-dose vial in a 
box of 10
2.46 2 1.3 6.6
OPV 25-dose vial 1.0 1 1.4 1.4
New schedule (Liquid penta + 2 IPV + 1 OPV) with IPV in a 1-dose vial 69.3
New schedule (Liquid penta + 2 IPV + 1 OPV) with IPV in 
a 10-dose vial
48.7
OPV: oral polio vaccine; DTPw: diphtheria-tetanus-whole cell pertussis; Hib: Haemophilus influenzae b; HepB: hepatitis B; 
IPV: inactivated polio vaccine; FIC: fully-immunized child
a Wastage factor = 1/(1 - wastage rate). The following wastage rates were used: single-dose vials, 5.0%; 5-dose vials, 10.0%; 
liquid vaccine in 10-dose vials, 25.0%. OPV wastage rate was estimated as 29.6%, according to the distributed and 
administered doses in Brazil in 2010.
b Vaccine volume per fully-immunized child = packed volume per dose multiplied by the number of doses, multiplied by the 
wastage factor.
of a missed vaccination. This is particularly important 
when considering the large number of new vaccines 
recently introduced in childhood immunization. New 
vaccine introduction also places significant pressure on 
the cold storage chain; as illustrated in Table 4, combi-
nation vaccines save space in the cold storage chain. 
Combination vaccines may facilitate the incorporation 
of IPV into the NIP.18 They simplify vaccine purchase, 
storage, and handling, reduce costs of labor and supplies, 
and reduce the need for additional clinic visits to avoid 
multiple injections, thereby improving compliance with 
vaccine recommendations.11,18
In recent years, Brazil has strengthened its public 
health capability to deliver domestic immunobiolog-
ical products by developing research and technology 
transfer agreements, allowing it to avoid dependence 
on importation of essential public health products. 
In 2007, approximately 83.0% of the vaccines used 
in the NIP were produced in Brazil.13 Production of 
an IPV-containing hexavalent combination, difficult 
but feasible, would allow Brazil to further reduce the 
number of injections and administration costs.
Our study has limitations. Costs of other combination 
vaccines containing IPV, such as diphtheria-tetanus-
acellular pertussis/IPV (DTPa/IPV), DTPa/HepB/IPV, 
or DTPa/Hib/IPV, were not taken into account in this 
analysis because they were not being considered by the 
Ministry of Health. Administration costs were also not 
taken into account. Because of the concomitant switch 
from DTP/Hib and HepB to a pentavalent combination 
vaccine, the main driver of the cost for IPV introduction 
in Brazil was the cost of the vaccine. This may not be the 
case in other countries considering IPV introduction.
The costs of the NID involve more than purchasing vaccines, 
estimated in this study as US$6,800,740.00 per NID. The 
costs of the two NID amounted US$24.8 million in 2010, 
on average US$12.4 million for each NID, including 
vaccine supply. The efforts to conduct an NID almost 
doubles vaccine costs (NIP Coordination information), 
and these costs were not considered in our study.
Replacing an all-OPV with an IPV-based immuniza-
tion schedule poses many programmatic challenges; 
these include ensuring vaccine supply, training health 
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care staff to administer the new vaccine, and assuring 
high vaccination coverage. Incorporating IPV in routine 
immunization would incur costs related to social 
mobilization, educational initiatives, health care staff 
training and supervision, and redesign of stationery, 
which were not included in this study.
In May 2012, the World Health Assembly (the deci-
sion-making body of the WHO) declared eradi-
cation of polio as a programmatic emergency for 
global public health. The Polio Eradication Endgame 
Strategic Plan (2013-2018) outlines a comprehensive 
approach to complete polio eradication, including 
eradication of both wild and vaccine-related viruses.23 
Introducing at least 1 dose of IPV in routine immuni-
zation is a key point in this strategy; its primary aim is 
to preserve immunity against type-2 poliovirus while 
globally replacing trivalent OPV (tOPV) with bivalent 
OPV (bOPV) containing types 1 and 3 vaccine polio-
virus.23 In April 2014, 36.0% of the 194 WHO Member 
States reported they have already introduced IPV in 
their immunization initiatives.24
IPV prices are dropping in the international market. 
IPV cost US$5.98 per dose in 2012 and US$2.80 in the 
2014 Revolving Funding Program of the Pan American 
Health Organization (PAHO). IPV is becoming avail-
able at approximately US$1.00 per dose in 10-dose 
vials for GAVI Alliance (formerly the Global Alliance 
for Vaccines and Immunizations) eligible countries in 
2014.24 For middle-income countries, IPV will be avail-
able at US$2.10-US$3.30 per dose in 10-dose presen-
tation. Another supplier is offering IPV at US$1.90 per 
dose in 5-dose presentation.24 This price reduction will 
allow more countries to be able to introduce at least 
one dose of IPV in routine childhood immunization.
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